…
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
InMode Ltd is an Israeli medical technology company that develops and commercializes minimally invasive and non‑invasive aesthetic treatment platforms primarily using radiofrequency and other energy‑based technologies. Long‑term growth may be supported by aging demographics, rising demand for non‑surgical cosmetic procedures, international expansion and ongoing product innovation that can generate recurring device and consumable sales. Investors may find the company attractive because it appears positioned with differentiated technology and a business model tied to physician adoption and procedure volumes.
Investors should monitor material risks including sensitivity to discretionary healthcare spending and procedure volumes, competitive pressure from larger med‑tech firms, regulatory and clinical approval requirements, and execution risk in sustaining product innovation and global commercial expansion.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 110.33M | 143.47M | 217.27M | 201.47M | 168.00M |
| Minority interest | - | - | 0.00M | 0.00M | -0.10M |
| Net income | 93.83M | 181.28M | 197.92M | 161.52M | 164.97M |
| Selling general administrative | 11.69M | 10.03M | 9.23M | 9.93M | 8.41M |
| Selling and marketing expenses | 180.58M | 181.37M | 193.04M | 160.58M | 119.35M |
| Gross profit | 290.97M | 317.07M | 411.34M | 380.79M | 303.97M |
| Reconciled depreciation | 0.69M | 0.73M | 0.62M | 0.68M | 0.52M |
| Ebit | 110.33M | 143.47M | 217.27M | 197.85M | 167.48M |
| Ebitda | 111.03M | 144.20M | 217.89M | 198.53M | 167.99M |
| Depreciation and amortization | 0.69M | 0.73M | 0.62M | 0.68M | 0.52M |
| Operating income | 85.39M | 112.53M | 195.66M | 197.85M | 167.48M |
| Other operating expenses | 285.11M | 282.29M | 296.39M | 256.42M | 190.09M |
| Interest expense | - | - | - | 3.61M | 0.42M |
| Tax provision | 16.50M | -37.81M | 19.35M | 39.95M | 2.93M |
| Interest income | 24.94M | 30.94M | 21.61M | 3.61M | 0.53M |
| Net interest income | 24.94M | 30.94M | 21.61M | 3.61M | 0.53M |
| Income tax expense | 16.50M | -37.81M | 19.35M | 39.95M | 2.93M |
| Total revenue | 370.50M | 394.82M | 492.05M | 454.27M | 357.56M |
| Total operating expenses | 205.58M | 204.53M | 215.68M | 182.93M | 136.50M |
| Cost of revenue | 79.53M | 77.75M | 80.71M | 73.48M | 53.59M |
| Total other income expense net | 24.94M | 30.94M | 21.61M | 3.61M | 0.53M |
| Net income from continuing ops | 93.83M | 181.28M | 197.92M | 161.52M | 165.07M |
| Net income applicable to common shares | - | - | - | 161.52M | 164.97M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 766.43M | 785.67M | 863.29M | 644.41M | 478.54M |
| Other current assets | 4.63M | 17.38M | 15.00M | 13.83M | 8.40M |
| Total liab | 83.23M | 81.85M | 75.91M | 89.79M | 62.74M |
| Total stockholder equity | 683.20M | 703.81M | 787.37M | 554.62M | 415.80M |
| Other current liab | 49.61M | 35.87M | 36.84M | 50.53M | 28.06M |
| Common stock | 0.25M | 0.25M | 0.24M | 0.24M | 0.24M |
| Capital stock | 0.25M | 0.25M | 0.24M | 0.24M | 0.24M |
| Retained earnings | 968.53M | 874.70M | 693.43M | 495.51M | 333.99M |
| Other liab | - | - | - | 4.26M | 7.58M |
| Other assets | - | - | - | 7.07M | 2.10M |
| Cash | 302.54M | 155.33M | 144.41M | 97.54M | 68.14M |
| Total current liabilities | 70.74M | 69.85M | 64.14M | 82.02M | 51.85M |
| Current deferred revenue | - | 16.75M | 10.92M | 13.80M | 13.80M |
| Net debt | -289.31M | -147.51M | -135.39M | -92.58M | -64.83M |
| Short term debt | 3.22M | 2.51M | 2.40M | 1.45M | 1.21M |
| Short long term debt total | 13.23M | 7.82M | 9.02M | 4.96M | 3.31M |
| Other stockholder equity | -285.65M | -170.80M | 95.38M | 66.36M | 82.89M |
| Property plant equipment | - | - | - | 7.37M | 5.72M |
| Total current assets | 698.62M | 714.45M | 845.33M | 629.37M | 470.11M |
| Long term investments | 0.70M | 0.70M | 0.70M | 0.60M | 0.60M |
| Net tangible assets | - | - | - | 554.62M | 415.80M |
| Short term investments | 252.79M | 441.14M | 597.19M | 449.84M | 347.78M |
| Net receivables | 49.28M | 41.05M | 43.63M | 42.09M | 33.17M |
| Inventory | 89.37M | 59.55M | 45.09M | 39.90M | 21.03M |
| Accounts payable | 17.91M | 13.78M | 13.97M | 16.24M | 8.78M |
| Accumulated other comprehensive income | 0.07M | -0.34M | -1.68M | -7.49M | -1.32M |
| Non currrent assets other | 3.00M | 3.18M | 3.67M | 3.97M | 0.77M |
| Non current assets total | 67.81M | 71.22M | 17.96M | 15.04M | 8.43M |
| Capital lease obligations | 8.23M | 7.82M | 9.02M | 4.96M | 4.52M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 187.00M | 162.21M | -122.65M | -109.47M | -159.17M |
| Change to liabilities | - | - | - | 8.66M | 5.04M |
| Total cashflows from investing activities | 186.03M | 162.21M | -136.06M | -109.47M | -160.11M |
| Total cash from financing activities | -126.06M | -282.77M | 5.50M | -41.09M | -15.02M |
| Change to operating activities | - | - | - | 16.15M | 7.74M |
| Net income | 93.83M | 181.28M | 197.92M | 161.52M | 165.07M |
| Change in cash | 147.21M | 10.92M | 46.87M | 29.40M | -0.80M |
| Begin period cash flow | 155.33M | 144.41M | 97.54M | 68.14M | 68.94M |
| End period cash flow | 302.54M | 155.33M | 144.41M | 97.54M | 68.14M |
| Total cash from operating activities | 85.26M | 132.66M | 176.83M | 181.58M | 174.88M |
| Issuance of capital stock | - | - | - | - | 0.00M |
| Depreciation | 0.69M | 0.73M | 0.62M | 0.68M | 0.52M |
| Other cashflows from investing activities | - | - | -135.36M | - | - |
| Change to inventory | -14.50M | -14.45M | -5.20M | -18.87M | -6.04M |
| Change to account receivables | -11.13M | 0.25M | -18.31M | -10.41M | -10.54M |
| Sale purchase of stock | -127.44M | -285.38M | 0.00M | -42.64M | -35.37M |
| Other cashflows from financing activities | - | 2.61M | 5.50M | 1.55M | 20.34M |
| Change to netincome | - | - | - | 23.85M | 13.21M |
| Capital expenditures | 0.97M | 0.67M | 0.70M | 1.57M | 0.94M |
| Change in working capital | -24.30M | -7.07M | -41.44M | -4.47M | -3.81M |
| Stock based compensation | 11.13M | 16.57M | 23.60M | 24.45M | 11.96M |
| Other non cash items | 0.97M | -3.66M | -3.69M | -0.69M | 1.91M |
| Free cash flow | 84.28M | 132.00M | 176.12M | 180.00M | 173.95M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| INMD InMode Ltd |
-0.28 2.20% |
12.42 | 12.29 | 10.48 | 2.28 | 1.36 | 0.96 | 5.15 |
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
| Name | Title | Year Born |
|---|---|---|
| Mr. Yair Malca | Chief Financial Officer | 1978 |
| Mr. Alon Yaari | VP of Operations | NA |
| Ms. Nava Tal-Launer | Chief Information Officer | NA |
| Mr. Shakil Lakhani | Pres of North America | 1983 |
| Dr. Spero Theodorou M.D. | Chief Medical Officer | 1972 |
| Mr. Moshe Mizrahy | Chairman & CEO | 1953 |
| Dr. Michael Kreindel | CTO & Director | 1968 |
| Mr. Shakil Lakhani | President of North America | 1983 |
| Mr. Alon Yaari | Vice President of Operations | NA |
| Dr. Michael Kreindel | Co-Founder, CTO & Director | 1968 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.